About 64% of the global population under age 50 has HSV-1, the virus most commonly associated with oral herpes. That translates to roughly 3.8 billion people worldwide, based on 2020 estimates from the World Health Organization. It is, by a wide margin, one of the most common infections on the planet.
Global Numbers at a Glance
The WHO’s 2020 data remains the most recent comprehensive estimate available. Of the 3.8 billion people infected, the vast majority carry the virus orally, typically as the result of childhood infection. Most people pick up HSV-1 through nonsexual contact during their early years: a kiss from a parent or relative, shared utensils, or other casual skin-to-skin contact.
A smaller but significant portion of those infections are genital. An estimated 376 million people worldwide had genital HSV-1 infections in 2020, a number the WHO highlighted in a December 2024 report. Genital HSV-1 is typically acquired through oral sex during adolescence or adulthood rather than through childhood contact.
Why Rates Vary So Much by Country
That 64% global figure masks enormous regional differences. In lower-income countries, particularly across Africa and South-East Asia, HSV-1 prevalence among adults often exceeds 80% or even 90%. Nearly everyone acquires the virus in early childhood, well before they become sexually active. In wealthier countries like the United States and those in Western Europe, childhood infection rates have been declining for decades, likely due to smaller household sizes, improved hygiene, and less crowded living conditions.
This decline has a counterintuitive consequence. People who reach adolescence without HSV-1 have no existing immunity to the virus, which means their first exposure can happen during sexual contact instead. That’s a key reason genital HSV-1 infections have become more common in high-income countries even as overall HSV-1 rates have dropped.
Prevalence by Age in the United States
U.S. data from the CDC illustrates how infection accumulates over a lifetime. Among Americans aged 14 to 49, HSV-1 prevalence rises steadily with each decade of life:
- Ages 14 to 19: 27.0%
- Ages 20 to 29: 41.3%
- Ages 30 to 39: 54.1%
- Ages 40 to 49: 59.7%
These numbers are notably lower than the global average, reflecting the delayed acquisition pattern seen in wealthier nations. By age 40, roughly 6 in 10 Americans carry the virus, compared to a global rate that approaches or exceeds that figure by young adulthood in many regions.
Gender Differences
Women are slightly more likely to carry HSV-1 than men. In the U.S., age-adjusted prevalence is about 50.9% among women and 45.2% among men, a statistically significant gap. Globally, a similar pattern holds for genital HSV-1 specifically: about 10.5% of women aged 15 to 49 have genital HSV-1 compared to 9.9% of men. The difference is partly biological, as mucosal tissue in the female genital tract is more susceptible to viral entry during exposure.
Most People Never Know They Have It
The reason HSV-1 spreads so effectively is that the majority of carriers have no obvious symptoms. Many people who test positive for HSV-1 antibodies have never had a recognizable cold sore. The virus establishes itself in nerve cells and remains dormant for long stretches, occasionally reactivating and reaching the skin surface without producing visible sores.
This process, called viral shedding, is how most transmission happens. Research from the University of Washington tracked shedding patterns in people with genital HSV-1 and found that participants shed the virus on about 12% of days at two months after infection, dropping to around 7% of days by 11 months. In most instances, participants had no symptoms while shedding. Oral HSV-1 follows a similar pattern: the virus periodically appears in saliva even when no cold sore is present.
HSV-1 vs. HSV-2
HSV-1 and HSV-2 are closely related but behave differently. HSV-2 is primarily a genital infection and far less common, affecting about 13% of people aged 15 to 49 globally (roughly 520 million people). HSV-2 prevalence is significantly higher in women (17.0%) than men (9.7%), and it causes more frequent genital outbreaks than HSV-1 does when it infects the same area.
Genital HSV-1 tends to recur less often and shed less frequently over time compared to genital HSV-2. That’s one reason clinicians increasingly distinguish between the two types when diagnosing genital herpes, since the long-term outlook differs considerably. Having oral HSV-1 also provides partial (though not complete) protection against acquiring HSV-2, because the immune response to one type offers some cross-reactivity against the other.
Why the Numbers Keep Shifting
In many high-income countries, childhood HSV-1 rates have been falling for at least two generations. Fewer children are getting infected young, which means a growing share of teenagers and young adults are encountering the virus for the first time through intimate contact. The result is a demographic shift: overall HSV-1 prevalence drops slightly, but genital HSV-1 cases rise. In lower-income settings, where childhood acquisition remains near-universal, this shift hasn’t occurred in the same way.
There is no vaccine for HSV-1 or HSV-2, and because most carriers don’t know they’re infected, the virus circulates easily through populations regardless of public health efforts. Standard blood tests can detect HSV-1 antibodies, but routine screening isn’t recommended in most countries because a positive result doesn’t distinguish between oral and genital infection, and the psychological impact of a diagnosis often outweighs the clinical significance for someone who has never had symptoms.